Inspire Advisors LLC Makes New $78,000 Investment in OPKO Health, Inc. (NASDAQ:OPK)

Inspire Advisors LLC purchased a new stake in OPKO Health, Inc. (NASDAQ:OPK) in the 1st quarter, HoldingsChannel reports. The fund purchased 47,130 shares of the biotechnology company’s stock, valued at approximately $78,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Oak Thistle LLC bought a new position in shares of OPKO Health in the first quarter valued at $26,000. Cerity Partners LLC purchased a new position in OPKO Health during the first quarter worth about $36,000. Wealth Enhancement Advisory Services LLC boosted its position in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares during the last quarter. Pallas Capital Advisors LLC purchased a new position in OPKO Health in the first quarter valued at about $43,000. Finally, Zacks Investment Management bought a new stake in shares of OPKO Health in the fourth quarter valued at $49,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Price Performance

NASDAQ:OPK opened at $1.35 on Wednesday. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -19.28 and a beta of 1.34. The business has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.48. OPKO Health, Inc. has a 1 year low of $1.21 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28.

OPKO Health (NASDAQ:OPK) last released its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). The business had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The business’s revenue for the quarter was down 13.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.12) EPS. Equities analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. LADENBURG THALM/SH SH raised OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Thursday, May 1st. Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Monday, May 5th. Finally, JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health presently has an average rating of “Moderate Buy” and a consensus price target of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.